ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion

Aumolertinib (Aumseqa)

Treatment of non-small cell lung cancer in adults.

CHMP opinion 12 Nov 2026 · SFL Pharmaceuticals Deutschland GmbH

Research

Oncology · Cancer Commun (Lond) · 2024-07-17

Secondary analysis of the phase III AENEAS trial: in 106 patients with untreated EGFR-mutated advanced NSCLC and baseline CNS metastases, aumolertinib prolonged median CNS PFS vs gefitinib (29.0 vs 8.3 months; HR 0.31). No new safety findings.

Secondary analysisn = 106
Lu et al. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)
Oncology · J Clin Oncol · 2022-05-17

In 429 untreated patients with advanced EGFR-mutated NSCLC, aumolertinib prolonged median PFS versus gefitinib (19.3 vs 9.9 months; HR 0.46, 95% CI 0.36–0.60). Response rates and grade ≥3 adverse events were similar; rash and diarrhoea were less common.

RCTn = 429
Lu et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.